Vienna-based digital health company Nyra Health has raised €20 million in Series A funding to expand its AI-powered neurotherapy platform internationally and accelerate product development. The round was led by Armira Growth, with renewed participation from Wellington Partners, Crane Venture Partners, which now oversees MassMutual Ventures’ investments, and EVER Pharma.
The company plans to use the capital to scale across the DACH region, expand into the United States, and further develop its multimodal AI platform to establish a new global standard for data-driven neurorehabilitation.
Nyra Health’s MDR Class IIa-certified therapy software, myReha, is currently used in more than 100 neurological clinics and is integrated into the standard care program of the German Pension Insurance, Europe’s largest rehabilitation provider. The platform is automatically reimbursed by 28 statutory and private health insurers, providing access to structured, AI-based home therapy for more than 40 million insured individuals.
The company addresses a significant gap in neurological care, particularly after hospital discharge, when therapy intensity often declines. Neurological diseases such as stroke, dementia, and traumatic brain injury generate €65 billion in annual costs in Germany alone, largely due to insufficient follow-up care. Nyra Health’s platform enables continuous therapy from inpatient treatment through long-term outpatient care, increasing therapy density during hospital stays and ensuring structured aftercare over several months.
At the core of the platform is myReha, which enables patients to train speech, cognition, fine motor skills, and everyday abilities with AI-supported, real-time feedback. Proprietary speech models analyze pathological speech at the level of pronunciation, word retrieval, syntax, and semantic structure, while continuously evaluating reaction times, error patterns, and training dynamics. Based on this data, therapy automatically adapts to performance level, fatigue, and progress. A randomized controlled trial demonstrated that the additional use of myReha led to significantly greater improvements in cognitive and language functions compared to standard therapy.
Nyra Insights, the company’s clinical management system, enables therapists to monitor language development, therapy intensity, and progress curves in real time, adjust programs, and automatically generate documentation. The platform also includes an AI-supported Content Studio that dynamically creates personalized therapy content based on individual performance data, forming a continuous loop of analysis, content adaptation, and training control .
With the new funding, Nyra Health will deepen its integration with additional clinic groups across the DACH region and expand reimbursement models in Germany, Austria, and Switzerland. The company is also preparing for a U.S. market launch in collaboration with an international pharmaceutical partner. In parallel, Nyra Health is advancing its multimodal AI models for therapeutic interaction and diagnostics through a €4.2 million funded research project in collaboration with leading U.S. research universities .
Nyra Health was founded by an interdisciplinary team specializing in neurology, machine learning, and regulatory affairs. The company is certified under ISO 13485 and ISO 27001 standards and has published eleven scientific papers in leading clinical and technological journals .
KEY QUOTES
Neurological rehabilitation can be made significantly more effective through digital solutions, especially in the area of speech ability. nyra health is considered a true category creator with a proprietary AI-based solution that seamlessly connects the entire care chain—from inpatient therapy to outpatient aftercare to home use—for the first time. We were also particularly impressed by the strong clinical evidence and deep integration into the German standard of care, which already gives nyra health access to over 40 million insured individuals. On this basis, the company is ideally positioned to define the market for digital neurorehabilitation internationally as well.
Christian Figge, Managing Partner, Armira Growth
From the outset, our goal was to make our services widely available to those affected. Everyone who needs therapy after a stroke or other neurological disease should have access to effective, individualized care—regardless of where they live or how well their own healthcare system is set up. With this round of financing, we are taking another step in this direction.
Moritz Schöllauf, CEO and Co-Founder, Nyra Health
